Active — Not RecruitingNot Applicable

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

Germany1,191 participantsStarted 2018-07-17

Plain-language summary

Systematic assessment of survival data of patients who have been tested with EndoPredict®; prospective proof that patients with low risk classification by EndoPredict® (EPclin) can safely forgo chemotherapy and be treated with endocrine therapy alone.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Informed consent
✓. Tested with EndoPredict within the previous 6 months before inclusion
✓. Age ≥ 18 years
✓. Patients with primary invasive breast cancer, Stage I/II
✓. ER-positive
✓. HER2-negative
✓. N0 or N1 (1-3 positive lymph nodes)
✓. T1 - T3

Exclusion criteria

✕. Inflammatory breast cancer
✕. Bilateral breast cancer
✕. Breast cancer in the last 10 years
✕. Other invasive malignancies in the last 5 years

What they're measuring

Distant metastasis free survival

Timeframe: 10 years

Trial details

NCT IDNCT03503799

SponsorNorth Eastern German Society of Gynaecological Oncology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2032-10-01

View on ClinicalTrials.gov More Primary Invasive Breast Cancer trials